{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:40:21Z","timestamp":1792276821367,"version":"4.4.0"},"reference-count":33,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"DOI":"10.1080\/13543784.2026.2750463","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:57:03Z","timestamp":1792033023000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Zovegalisib for\n                    <i>PIK3CA<\/i>\n                    -driven vascular and lymphatic malformations: a drug evaluation"],"prefix":"10.1080","author":[{"given":"Emmanuel","family":"Seront","sequence":"first","affiliation":[{"name":"University of Louvain","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Van Damme","sequence":"additional","affiliation":[{"name":"University of Louvain","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Coulie","sequence":"additional","affiliation":[{"name":"Cliniques universitaires St Luc, University of Louvain","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miikka","family":"Vikkula","sequence":"additional","affiliation":[{"name":"Human Molecular Genetics","place":["Brussels, Belgium"]},{"name":"de Duve Institute","place":["Brussels, Belgium"]},{"name":"WEL Research Institute","place":["Wavre, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence M.","family":"Boon","sequence":"additional","affiliation":[{"name":"Cliniques universitaires St Luc, University of Louvain","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71614"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009688"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000598"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318145"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318142"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.11.011"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01898-y"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.05.006"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.12.069"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104637"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOVA.0000000000000064"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-023-01414-9"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76004"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0934-z"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173095"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg0809"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0217-9"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1270"},{"key":"e_1_3_5_21_1","unstructured":"European Medicines Agency. Vijoice (alpelisib): summary of opinion (initial authorisation). Amsterdam The Netherlands: Committee for Medicinal Products for Human Use; 2026 [cited 2026 Aug 20]. Available from: www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-vijoice_en.pdf"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100969"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOVA.0000000000000115"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0944"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03564-z"},{"key":"e_1_3_5_26_1","unstructured":"Kaken Pharmaceutical Co. Ltd. Announcement of the result of phase iii clinical trial of KP-001 in Japan. Tokyo Japan; 2025 Nov 10 [cited 2026 Aug 20]. Available from: www.kaken.co.jp\/english\/"},{"key":"e_1_3_5_27_1","volume-title":"Presented at: International Society for the Study of Vascular Anomalies (ISSVA) World Congress","author":"Graupera M","year":"2026","unstructured":"Graupera M, Sisk B, Adams DM, et al. Zovegalisib (RLY-2608), a novel, mutant-selective PI3K\u03b1 inhibitor, induces lesion regression with minimal hyperinsulinemia in murine models of PIK3CA-mutant vascular malformations [abstract 404]. In: Presented at: International Society for the Study of Vascular Anomalies (ISSVA) World Congress. Philadelphia (PA), USA; 2026 May 19\u201322."},{"key":"e_1_3_5_28_1","volume-title":"Presented at: International Society for the Study of Vascular Anomalies (ISSVA) World Congress","author":"Sisk B","year":"2026","unstructured":"Sisk B, Adams DM, Hammill AM, et al. Initial results of zovegalisib (RLY-2608), a mutant-selective PI3K\u03b1 inhibitor, in adult and pediatric patients with PIK3CA-driven vascular malformations [late-breaking abstract]. In: Presented at: International Society for the Study of Vascular Anomalies (ISSVA) World Congress; Philadelphia (PA), USA; 2026 May 19\u201322."},{"key":"e_1_3_5_29_1","unstructured":"Relay Therapeutics Inc. Relay therapeutics announces initial clinical data demonstrating that zovegalisib has potential for differentiated safety and efficacy in patients with PIK3CA-driven vascular anomalies. Press release. Cambridge (MA) USA; 2026 May 19 [cited 2026 Aug 20]. Available from: www.relaytx.com"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1086"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133740"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105636"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006284"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljag409"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2750463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2750463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2750463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:59:28Z","timestamp":1792274368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2750463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":33,"alternative-id":["10.1080\/13543784.2026.2750463"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2750463","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}